查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1333923

阿霉素市场：现状分析与预测（2022-2030）

Doxorubicin Market: Current Analysis and Forecast (2022-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于技术进步和频繁的产品发布，预计阿霉素市场在预测期内将以 7% 的复合年增长率强劲增长。例如，2019年12月，Capstone宣布盐酸阿霉素脂质体注射液获得 FDA 批准和欧盟许可。

根据剂型，市场分为冻干粉针剂和阿霉素注射剂。冻干粉细分市场在 2021 年获得了主要份额。冻干粉因其保质期长且易于运输和储存而被广泛使用。而且，冻干粉的高稳定性也是该细分市场在细分市场中占有较大份额的重要原因。

根据应用，市场分为膀胱癌、卡波西肉瘤、白血病、淋巴瘤、乳腺癌等。在预测期内，阿霉素市场的白血病细分市场预计将以更高的复合年增长率增长。白血病的高患病率和该疾病病例的快速增加是推动该细分市场增长的关键因素。例如，美国癌症协会估计，2023 年将报告 59,610 例新的白血病病例和 23,710 例白血病死亡病例。

根据分销渠道，市场分为医院药房、零售药房和网上药房。医院药房部门在 2021 年获得了主要份额。这主要是因为患者更喜欢医院药房，因为它们拥有分发药品所需的许可证，而且它们位于医院内，更容易获得药品。

为了更好地了解该行业的市场采用情况，市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、意大利、西班牙、欧洲其他地区）、亚太地区（中国、日本、印度、韩国、澳大利亚等亚太地区国家）及世界其他地区。2021年阿霉素市场中，北美地区占据压倒性份额。这主要是由于老年人口的增加以及老年人癌症患病率的增加。此外，北美市场产品投放的增加和市场参与者的扩大也促进了北美阿霉素市场的增长。例如，根据人口研究所的数据，美国65岁及以上人口数量将从2018年的5200万增加近一倍，达到2060年的9500万，65岁及以上人口占总人口的比例将从16%增加到9500万到2060年，预计将增加至23%。

目录

第一章 市场介绍

  • 市场定义
  • 主要目的
  • 利益相关者
  • 限制

第二章 研究方法或假设

  • 调查过程
  • 调查方法
  • 受访者简介

第三章市场总结

第 4 章执行摘要

第五章新型冠状病毒感染（COVID-19）对全球阿霉素市场的影响

第六章2020-2028年全球阿霉素市场收入

第七章 市场洞察的表述

  • 冻干粉
  • 阿霉素注射液

第 8 章按应用划分的市场洞察

  • 膀胱癌
  • 卡波西肉瘤
  • 白血病
  • 淋巴瘤
  • 乳腺癌
  • 其他

第 9 章按分销渠道划分的市场洞察

  • 医院药房
  • 零售药店
  • 网上药店

第10章按地区划分的市场洞察

  • 北美阿霉素市场
    • 美国
    • 加拿大
    • 其他北美
  • 欧洲阿霉素市场
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 亚太阿霉素市场
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 韩国
    • 亚太地区其他国家
  • 其他地区阿霉素市场

第十一章阿霉素市场动态

  • 市场驱动力
  • 市场挑战
  • 影响分析

第十二章阿霉素市场机会

第十三章阿霉素市场趋势

第十四章需求侧和供给侧分析

  • 需求侧分析
  • 供给侧分析

第十五章价值链分析

第十六章价格分析

第十七章战略洞察

第18章 竞争场景

  • 竞争格局
    • 波特五力分析

第十九章公司简介

  • Intas Pharmaceuticals Ltd.
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Cadila Pharmaceuticals
  • Meiji Holdings Co., Ltd.
  • Johnson & Johnson Private Limited.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Baxter

第二十章 免责声明

简介目录
Product Code: UMHE212094

Doxorubicin is an antibiotic with a broad antineoplastic activity that is obtained from a Streptomyces peucetius bacterium and is injected in the form of hydrochloride. This drug is used to treat different cancers such as kidney, ovarian, liver, ovarian, and others. This drug works by with interfering the DNA of cancerous cells and preventing them to grow and divide. The rising prevalence of cancerous diseases is the primary factor for the market growth of the doxorubicin market. For instance, according to the World Health Organisation (WHO), cancer is the primary cause of death worldwide accounting for 10 million deaths in 2020.

Doxorubicin Market is expected to grow at a strong CAGR of 7% during the forecast period owing the technological advancements and frequent product launches. For instance, In December 2019, Capstone announced the FDA Approval and EU Authorization of Doxorubicin Hydrochloride Liposome Injection.

Based on drug formulation, the market is segmented into lyophilized powder and doxorubicin injection. The lyophilized powder segment acquired a major share in 2021. The Lyophilized powders are commonly used because they have a longer shelf life and are easy to transport and stored. Further, the lyophilized powder is more stable which is also an important reason for the significant market share of the segment in the doxorubicin market.

Based on the application, the market is segmented into bladder cancer, kaposi sarcoma, leukemia, lymphoma, breast cancer, and others. The leukemia segment is expected to grow with a higher CAGR in the doxorubicin market during the forecast period. The prevalence of leukemia is high and the cases of the disease are growing at a rapid pace is an important factor responsible for the growth of the segment. For instance, as per the American Cancer Society, an estimated 59,610 new cases of leukemia and 23,710 deaths from leukemia will report in 2023.

Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment acquired a major share in 2021. This is mainly due to the hospital pharmacies having the necessary licenses for the distribution of these and patients also prefer hospital pharmacies due to their presence inside the hospital makes the drug availability easy.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North American region held dominant share in doxorubicin market in 2021. This is mainly due to the increasing prevalence of the geriatric population and the increased prevalence of cancer in them. Further, the increasing product launches and expansion of market players in the North American market are also responsible for the market growth of Doxorubicin in North America. For instance, as per the Population Reference Bureau, the number of Americans 65 and older is expected to nearly double, from 52 million in 2018 to 95 million in 2060, and the share of those 65 and older in the total population will increase from 16% to 23%.

Some of the major players operating in the market include: Intas Pharmaceuticals Ltd.; Cipla Inc.; Dr. Reddy's Laboratories Ltd.; Cadila Pharmaceuticals; Meiji Holdings Co., Ltd.; Johnson & Johnson Private Limited.; Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; and Baxter.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Doxorubicin Market
  • 2.2. Research Methodology of the Doxorubicin Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL DOXORUBICIN MARKET COVID-19 IMPACT

6 GLOBAL DOXORUBICIN MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY DRUG FORMULATION

  • 7.1. Lyophilized Powder
  • 7.2. Doxorubicin Injection

8 MARKET INSIGHTS BY APPLICATION

  • 8.1. Bladder Cancer
  • 8.2. Kaposi Sarcoma
  • 8.3. Leukemia
  • 8.4. Lymphoma
  • 8.5. Breast Cancer
  • 8.6. Others

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

  • 9.1. Hospital Pharmacy
  • 9.2. Retail Pharmacy
  • 9.3. Online Pharmacy

10 MARKET INSIGHTS BY REGION

  • 10.1. North America Doxorubicin Market
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe Doxorubicin Market
    • 10.2.1. Germany
    • 10.2.2. UK
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific Doxorubicin Market
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of APAC
  • 10.4. Rest of the World Doxorubicin Market

11 DOXORUBICIN MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 DOXORUBICIN MARKET OPPORTUNITIES

13 DOXORUBICIN MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

  • 18.1. Competitive Landscape
    • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

  • 19.1. Intas Pharmaceuticals Ltd.
  • 19.2. Cipla Inc.
  • 19.3. Dr. Reddy's Laboratories Ltd.
  • 19.4. Cadila Pharmaceuticals
  • 19.5. Meiji Holdings Co., Ltd.
  • 19.6. Johnson & Johnson Private Limited.
  • 19.7. Novartis AG
  • 19.8. Pfizer Inc.
  • 19.9. Sun Pharmaceutical Industries Ltd.
  • 19.10. Baxter

20 DISCLAIMER